An analysis of China's national essential medicines policy

被引:0
|
作者
Xiaodong Guan
Huigang Liang
Yajiong Xue
Luwen Shi
机构
[1] Peking University,Department of Pharmacy Administration and Clinical Pharmacy
[2] Center for Health Management Systems,undefined
[3] College of Business,undefined
[4] East Carolina University,undefined
[5] International Research Center of Medicinal Administration,undefined
[6] Peking University,undefined
来源
Journal of Public Health Policy | 2011年 / 32卷
关键词
essential medicines; China; pharmaceutical policy; health-care reform;
D O I
暂无
中图分类号
学科分类号
摘要
Although China embraced the concept of essential medicines in 1979 and issued its first National Essential Medicines List in 1982, until recently China has lacked a comprehensive national essential drug policy. In its most recent health-care reform (2009–2012), the Chinese government explicitly proposed the establishment of a national essential medicines system, and made it one of five top priorities in the coming years. We review the evolution of China's essential medicines policies, explain the importance of fully implementing the essential medicines policy, and analyze recent policy developments surrounding essential medicines.
引用
收藏
页码:305 / 319
页数:14
相关论文
共 50 条
  • [31] Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: being AWaRe
    Budd, Emma
    Cramp, Emma
    Sharland, Mike
    Hand, Kieran
    Howard, Philip
    Wilson, Peter
    Wilcox, Mark
    Muller-Pebody, Berit
    Hopkins, Susan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (11) : 3384 - 3389
  • [32] Does a National Medicines Policy Improve Medicines Access and Utilisation?
    Pont, Lisa G.
    Kemp, Anna
    Roughead, Elizabeth E.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S291 - S292
  • [33] US changes trade policy on essential medicines
    Yamey, G
    BRITISH MEDICAL JOURNAL, 1999, 319 (7224): : 1521 - 1521
  • [34] A comparison of national essential medicines lists in the Americas
    Steiner, Liane
    Maraj, Darshanand
    Woods, Hannah
    Jarvis, Jordan
    Yaphe, Hannah
    Adekoya, Itunu
    Bali, Anjli
    Persaud, Nav
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2020, 44
  • [35] National Medicines Policy 2.0- what's changed and what's next?
    McLachlan, Andrew J.
    Aslani, Parisa
    AUSTRALIAN PRESCRIBER, 2023, 46 (04) : 72 - 74
  • [36] An analysis of the essential medicines policy in primary care: Findings from MedMinas project
    Luz, Tatiana Chama Borges
    Tavares, Noemia Urruth Leao
    Marques, Isabela Cristina
    de Castro, Ana Karine Sarvel
    Cota, Betania Barros
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Improving access to medicines and beyond: the national volume-based procurement policy in China
    Zhu, Zheng
    Wang, Quan
    Sun, Qiang
    Lexchin, Joel
    Yang, Li
    BMJ GLOBAL HEALTH, 2023, 8 (07):
  • [38] Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy
    Lipworth, Wendy
    Doran, Evan
    Kerridge, Ian
    Day, Richard
    AUSTRALIAN HEALTH REVIEW, 2014, 38 (02) : 160 - 168
  • [39] Anticancer medicines in Pakistan: An analysis of essential medicines lists
    Shukar, Sundus
    Anjum, Rehan
    Zhang, Jinwei
    Babar, Zaheer-Ud-Din
    Mobeen, Iqra
    Yang, Caijun
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (01) : 46 - 54
  • [40] National Medicines Policy 2.0: a vision for the future
    McLachlan, Andrew J.
    Aslani, Parise
    AUSTRALIAN PRESCRIBER, 2020, 43 (01) : 24 - 26